Trump’s Tariff Blitz: Pharmaceuticals and Chips in the Crosshairs

The Trump administration has launched investigations into imports of pharmaceuticals and semiconductors, citing national security concerns. These probes, initiated under Section 232 of the Trade Expansion Act of 1962, aim to impose tariffs to reduce reliance on foreign production. Pharmaceuticals and semiconductors, which are largely sourced from countries like India, China, and Taiwan, are seen as critical to U.S. security. While the administration argues that tariffs will boost domestic manufacturing, critics warn of potential shortages and increased costs for consumers. 

The move follows exemptions for smartphones and computers from steep reciprocal tariffs, signaling a strategic shift in trade policy. As markets react to these developments, the global economic landscape faces uncertainty.